<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?DTDIdentifier.IdentifierValue -//ES//DTD journal article DTD version 5.5.0//EN//XML?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName art550.dtd?><?SourceDTD.Version 5.5.0?><?ConverterInfo.XSLTName elsevier2nlmx2.xsl?><?ConverterInfo.Version 1?><?origin publisher?><?FILEmeta_OMTN465 xml ?><?FILEmain xml ?><?FILEmain pdf ?><?FILEgr1 jpg ?><?FILEgr2 jpg ?><?FILEgr3 jpg ?><?FILEgr4 jpg ?><?FILEgr5 jpg ?><?FILEgr6 jpg ?><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Ther Nucleic Acids</journal-id><journal-id journal-id-type="iso-abbrev">Mol Ther Nucleic Acids</journal-id><journal-title-group><journal-title>Molecular Therapy. Nucleic Acids</journal-title></journal-title-group><issn pub-type="epub">2162-2531</issn><publisher><publisher-name>American Society of Gene &#x00026; Cell Therapy</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6454098</article-id><article-id pub-id-type="publisher-id">S2162-2531(19)30058-7</article-id><article-id pub-id-type="doi">10.1016/j.omtn.2019.02.027</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Sikandar Hayat</given-names></name><email>sik_cpsp@yahoo.com</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="cor1" ref-type="corresp">&#x02217;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Pathology, PNS HAFEEZ Hospital, Pathology E-8, Islamabad, Islamabad 44400, Pakistan</aff><author-notes><corresp id="cor1"><label>&#x02217;</label>Corresponding author: Sikandar Hayat Khan, Department of Pathology, PNS HAFEEZ Hospital, Pathology E-8, Islamabad, Islamabad 44400, Pakistan. <email>sik_cpsp@yahoo.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>03</day><month>4</month><year>2019</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><day>07</day><month>6</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>03</day><month>4</month><year>2019</year></pub-date><volume>16</volume><fpage>326</fpage><lpage>334</lpage><permissions><copyright-statement>&#x000a9; 2019 The Author(s)</copyright-statement><copyright-year>2019</copyright-year><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="abs0010"><p>The traditional healthcare system is at the doorstep for entering into the arena of molecular medicine. The enormous knowledge and ongoing research have now been able to demonstrate methodologies that can alter DNA coding. The techniques used to edit or change the genome evolved from the earlier attempts like nuclease technologies, homing endonucleases, and certain chemical methods. Molecular techniques like meganuclease, transcription activator-like effector nucleases (TALENs), and zinc-finger nucleases (ZFNs) initially emerged as genome-editing technologies. These initial technologies suffer from lower specificity due to their off-targets side effects. Moreover, from biotechnology&#x02019;s perspective, the main obstacle was to develop simple but effective delivery methods for host cell entry. Later, small RNAs, including microRNA (miRNA) and small interfering RNA (siRNA), have been widely adopted in the research laboratories to replace lab animals and cell lines. The latest discovery of CRISPR/Cas9 technology seems more encouraging by providing better efficiency, feasibility, and multi-role clinical application. This later biotechnology seem to take genome-engineering techniques to the next level of molecular engineering. This review generally discusses the various gene-editing technologies in terms of the mechanisms of action, advantages, and side effects.</p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>transcription activator-like effector nucleases</kwd><kwd>TALENs</kwd><kwd>zinc-finger nucleases</kwd><kwd>ZFNs</kwd><kwd>RNAi</kwd><kwd>CRISPR/Cas9 technology</kwd></kwd-group></article-meta></front><body><sec id="sec1"><title>Main Text</title><p id="p0010">Over the last half century after post-DNA helical structure discovery, the world has seen a continuous staircase outburst of various molecular technologies, which are now heading forward toward translation&#x000a0;into clinical and laboratory practice.<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Given the availability of sequencing platforms, acquired wisdom about the micro-mechanics at work within the genetic apparatus, and the introduction of user-friendly nanotechnologies, it was possible for next-generation scientists to manipulate the genetic codes at various levels.<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> Over the last two decades we saw a plethora of molecular techniques, which allowed us to edit genes or their alter pathways, allowing humans for the first time to micro-edit the DNA codes and further to alter the mRNA fate through post-transcriptional modifications.<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref></p><p id="p0015">Principally, genome-wide editing techniques can be interpreted as methods where DNA sequences are changed by deletions, mRNA processing, and post-transcriptional modifications to result in altered gene expression, leading to functional behavior of proteins.<xref rid="bib4" ref-type="bibr">4</xref>, <xref rid="bib5" ref-type="bibr">5</xref> Common to these methods are three basic steps, including mechanisms for genetic tool entry into the cell and later nucleus; altering gene transcription and onward processing function; and, finally, the end-output in the shape of a suppressed, overexpressed, or simply an altered protein product.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> From a holistic point of view, the techniques involve an apparently simplistic concept involving multiple receptor-ligand interactions; varying cell entry modes like lipofection, sonification, and transfection; and further downstream pathway effects. Furthermore, these technologies are variable in terms of their specificity and sensitivity, off-target effects, finances, and technique expertise. The body&#x02019;s immune response to accept the foreign genetic elements within the cells can lead to the rejection of foreign tissues.</p><p id="p0020">Moreover, molecular knowledge, in terms of methodology differences, defining targetable diseases, innovative nanotechnology tools for gene editing, and ethical aspects, also needs to be understood. The platforms for these technologies are improving every day, with a plethora of new data appearing due to technology miniaturization and automation and newer discoveries to improve the yield and specificity of an&#x000a0;edited product. Alongside the developmental improvement in genome-wide engineering the regulatory work-up, standardization protocols need to be devised to reduce inter and intra-method imprecision, defining the indications and contraindications of every technique to help improve the concept of personalized medicine.</p><p id="p0025">This review briefly explains the available technologies, provides comparison and contrast between different genome-editing methods, and&#x000a0;identifies some newer versions of genome editing with possible bioethical concerns.</p><sec id="sec1.1"><title>Review Methodology</title><p id="p0030">PubMed searches with the keywords genome-editing techniques or gene-editing techniques in the last 10 and 5 years yielded a total of 4,466 and 4,054 references, except some historical and related references. Specific searches for articles dealing with specific genome-editing methods included conventional genome-editing systems (n&#x000a0;= 100), chemical methods (n&#x000a0;= 252), meganucleases (n&#x000a0;= 83), zinc-finger nucleases (ZFNs) (n&#x000a0;= 890), transcription activator-like effector nucleases (TALENs) (n&#x000a0;= 1,136), homing endonucleases (n&#x000a0;= 265), and CRISPR (n&#x000a0;= 11,421). The search was therefore limited to reviews showing conceptual information of common techniques and comparative information about ZFNs, TALENSs, and CRISPR technologies. Finally, the literature was searched for learning newer and advanced gene-editing methods and bioethical concerns associated with genome biotechnologies.</p></sec><sec id="sec1.2"><title>Genome-Editing Techniques</title><p id="p0035">The recent expansion and advancements in the field of biotechnology provided us with information and insight into the biochemical and molecular mechanisms to edit DNA and, thus, modify downstream pathways. To date, multiple biotechnologies have shown promise for clinical use, but the field of genome-editing technologies is rapidly evolving and improving. The new techniques seem promising, but the earlier ones have also been updated and improved. For simplicity and consolidation, an overview of genome-editing techniques is presented in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>.<fig id="fig1"><label>Figure&#x000a0;1</label><caption><p>A Consolidated Overview of Genome-Editing Techniques</p></caption><graphic xlink:href="gr1"/></fig></p><p id="p0040">Representative genome-editing techniques are discussed below.<list list-type="simple" id="olist0010"><list-item id="o0010"><label>(1)</label><p id="p0045">Conventional genome-editing technique. In the true sense, the technique may not relate with evolving genome-editing techniques. As highlighted in <xref rid="fig1" ref-type="fig">Figure&#x000a0;1</xref>, it includes homologous recombination related with gene intervention. While not much in vogue or lab use today, the technique is based on physiological processes involving a double-stranded repair system. However, some recent data have shown RAD52 protein to be important in mediating homologous recombination, and this protein therefore has been considered as a therapy target in certain cancers like BRCA 1 and 2 repair pathways.<xref rid="bib6" ref-type="bibr">6</xref>, <xref rid="bib7" ref-type="bibr">7</xref> However, the technique as of now could not gain widespread introduction due to the emergence of newer techniques.</p></list-item><list-item id="o0015"><label>(2)</label><p id="p0050">Chemical modalities of genome editing. Komiyama<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> utilized non-restriction enzyme methodology termed artificial restriction DNA cutter (ARCUT). This method uses pseudo-complementary peptide nucleic acid (pcPNA), whose job is to specify the cleavage site within the chromosome or the telomeric region. Once pcPNA specifies the site, excision here is carried out by cerium (CE) and EDTA (chemical mixture), which performs the splicing function.<xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Furthermore, the technology uses a DNA ligase that can later attach any desirable DNA within the spliced site. The advantage of this particular technique is that it can be used in high salt concentrations. Upon initial introduction, the technique looked quite appealing to the clinical market; however, later issues like increased turnaround time and specifically the manufacturing of site-specific pcPNA became huge hurdles (<xref rid="fig2" ref-type="fig">Figure&#x000a0;2</xref>).<xref rid="bib8" ref-type="bibr">8</xref>, <xref rid="bib9" ref-type="bibr">9</xref><fig id="fig2"><label>Figure&#x000a0;2</label><caption><p>Excision of Selective Site of dsDNA by Utilizing Artificial Restriction DNA Cutter</p></caption><graphic xlink:href="gr2"/></fig></p></list-item><list-item id="o0020"><label>(3)</label><p id="p0055">Homing endonuclease systems. Homing endocucleases (HEs) with this word &#x0201c;homing&#x0201d; practically is interpreted as lateral transmission of a genome DNA sequence. The general concept involves a DNA segment where a site is removed by the endocnulceases, which thus results in the formation of 2 segments of DNA fragment.<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> So what are these HEs? They are nucleases that occur naturally, with a size almost equivalent to 14&#x000a0;bp, and they are capable of splicing slightly larger DNA sequences.<xref rid="bib11" ref-type="bibr"><sup>11</sup></xref> Recently, the introduction of recombinant adeno-associated viruses (rAAVs) have allowed them as efficient vehicles for transporting genetic tools of genome engineering into the cell, as depicted in <xref rid="fig3" ref-type="fig">Figure&#x000a0;3</xref>.<xref rid="bib12" ref-type="bibr"><sup>12</sup></xref> Issues pertaining to this technology include engineering difficulties in the preparation of these nucleases as well as developing vectors for their entry into cells.<xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> Another issue with rAAV, though improving with better biotechnology, was off-target effects like reducing site specificity, less DNA integration, and possible host genome mutations.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref><fig id="fig3"><label>Figure&#x000a0;3</label><caption><p>Schematic Showing rAAV Entry, Movement within Cytoplasm, Attachment with DNA, and Integration with DNA Segment for Possible Genome Modification</p><p>The steps include the following: (1) entry of rAAV into cell, (2) uptake by exosome and transport within cytoplasm, (3) release of rAAV for entry into nucleus, (4) rAAV delivery of homing endocnulease (HE) and desirable DNA segment, (5) HE cut of the non-desirable DNA code, and (6) rAAV-delivered desirable DNA code replacement of the DNA.</p></caption><graphic xlink:href="gr3"/></fig></p></list-item><list-item id="o0025"><label>(4)</label><p id="p0060">Protein-based nuclease systems. These systems incorporate nuclease proteins for DNA sequence editing. The common techniques are described below.</p></list-item><list-item id="u0010"><p id="p0065">Meganucleases. Also termed molecular DNA scissors, these are large base pair structures that are sometimes found in the genome. Their potential to excise large pieces of DNA sequences was recently recognized as a genetic tool to modify DNA. This genetic potential has been manipulated in labs by modifying the recognition sites to create nicks, as required for DNA sequence change. These meganucleases are sometimes joined by proteins to create large variants like DmoCre and E-Drel, which can further provide nucleotide site-specific cleavage.<xref rid="bib15" ref-type="bibr"><sup>15</sup></xref> The technique revolves around two basic steps: first is the recognition of a cleavage site, and then endonucleases splice out the region.<xref rid="bib16" ref-type="bibr"><sup>16</sup></xref> The positive aspect related to meganucleases is less toxicity, as they are naturally occurring and provide very specific site cleavage. However, there are newer techniques now in the clinical arena that have not allowed them to flourish more.</p></list-item><list-item id="u0015"><p id="p0070">ZFNs. ZFNs are purely artificial structures generated by a combinatorial approach where restriction endonucleases are joined with zinc-finger-binding domain protein. <xref rid="fig4" ref-type="fig">Figure&#x000a0;4</xref> explains their mechanism of action in detail, where a binding protein domain identifies after reaching the desirable splice site, which is then cut at a specific codon by special restriction endonucleases called FokI. The biotechnology is restricted in terms of attachment with 3 codons on either side of the DNA chain. The technique in recent years has gained widespread popularity due to its simplicity and specificity, and it is being employed in clinical usage for certain diseases.<xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref><fig id="fig4"><label>Figure&#x000a0;4</label><caption><p>Schematic Showing Step by Step Zinc-Finger Nuclease-Induced Genome Editing</p><p>The mechanisms include the following: (1) ZFNs containing FokI endonucleases and protein-binding domains are introduced into the cell, (2) FokI and protein-binding domains are released to enter the nucleus, (3) protein-binding domains attach with DNA fragment to be removed, (3) FokI cuts out the identified DNA segment by creating double-stranded DNA break, and (4) the desirable DNA segment is inserted and integrated into the DNA sequence.</p></caption><graphic xlink:href="gr4"/></fig></p></list-item><list-item id="u0020"><p id="p0075">TALENs. TALENS almost resemble ZFNs in terms of manufacturing and mode of action. They are made by a similar principle where a restriction nuclease is bound to a DNA-binding protein domain called TAL effector.<xref rid="bib19" ref-type="bibr"><sup>19</sup></xref> The difference between TALENs and ZFNs is that the former can target 3 nt in one go and the latter can only address 1 nt, thus making TALENs slightly more site specific with fewer off-target effects.<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref> However, the techniques share many similarities (<xref rid="fig5" ref-type="fig">Figure&#x000a0;5</xref>).<fig id="fig5"><label>Figure&#x000a0;5</label><caption><p>Diagram Showing Mechanisms of Transcription Activator-like Effector Nucleases</p><p>The steps of gene editing include the following: (1) TALENs containing FokI endonucleases and TALE domains are introduced into the cell, (2) FokI and TALE domains are released to enter the nucleus, (3) TALE recognizes the non-desirable DNA segments and attaches with them, (4) FokI cleaves the non-desirable DNA segments, and (5) after the non-desirable DNA segments are cleaved, the desirable segment of DNA is incorporated into the DNA.</p></caption><graphic xlink:href="gr5"/></fig></p></list-item><list-item id="o0030"><label>(5)</label><p id="p0080">RNA DNA systems. These systems primarily include the different types of CRISPR methods. The concept of CRISPR is primitive and has been derived from an ancient immunity system, adopted in nature by some prokaryotic cells like Archea and probably some bacteria.<xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> CRISPR in itself has two components, including SPR termed sometimes as spacers, which are hallmarked by varying and differing nucleotide sequences, and probably each one of them represents a past exposure to foreign antigen. The CRI may represent the genetic memory for a bacterium and can be re-activated once encountered with a similar foreign antigen. CRI has similar nucleotides (repeats) representing like separators between different CRIs.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref>
<xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref> attempts to provide a basic overview of the CRISPR/Cas9 concept.<fig id="fig6"><label>Figure&#x000a0;6</label><caption><p>Schematic Demonstrating the Concept of CRISPR/Cas9 Interactions Leading to the Destruction of Viral Genome at the Selected Splice Site by the crRNA/gRNA</p></caption><graphic xlink:href="gr6"/></fig></p></list-item><list-item id="u0025"><p id="p0085">Cas especially Cas9 as depicted in <xref rid="fig6" ref-type="fig">Figure&#x000a0;6</xref> has a nuclease function. Whenever CRISPR RNA (crRNA; also termed guide RNA [gRNA]) guides the Cas9 protein regarding a possible antigenic threat, like a bacteriophage, it with the help of gRNA creates double-stranded DNA (dsDNA) nicks at the guided selected sites, causing a site-specific cleavage and, thus, destruction of the antigen.<xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> Moreover, the memory from the antigen is stored as spacer within CRISPR.<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></p></list-item><list-item id="u0030"><p id="p0090">This physiological role of Cas9/CRISPR as explained above had recently been extensively utilized for multiple clinical conditions.<xref rid="bib25" ref-type="bibr">25</xref>, <xref rid="bib26" ref-type="bibr">26</xref>, <xref rid="bib27" ref-type="bibr">27</xref> At the time of writing this review, the news broke about Lulu and Nana being claimed to be the first genetically modified babies, where the human genome was edited to create resistance against HIV infection.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> Specific crRNA/gRNA has been engineered, which can be introduced into cell nuclei and later Cas9 where the non-desirable dsDNA is associated with the Cas9 after guidance provided by the specific crRNA/gRNA. This complementary binding between gRNA and the non-desirable segment allows Cas9 to destroy the DNA fragment. In clinical and research practice, the created nick can be specifically filled by inserting the sequence of choice to change the non-desirable sequence of nucleotides.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref></p></list-item><list-item id="u0035"><p id="p0095">Over the last few years, CRISPR/Cas9 technology has gained widespread popularity on account of its simplicity and specificity, with different versions of the original now under research. Multiple experimentations and biotechnologies have been re-defining the CRISPR/Cas technologies into 3 distinct types of CRISPR-Cas types, based on crRNA processing and further action, including the following:</p></list-item><list-item id="u0040"><p id="p0100">Type 1 CRISPR/Cas system. This version utilized Cas5 or Cas6 for pre-processing of crRNA; further cleavage function needs Cas3, Cascade, and crRNA for interference.</p></list-item><list-item id="u0045"><p id="p0105">Type 2 CRISPR/Cas system. Though Cas9 typically functions under the guidance of crRNA to target DNA, RNase III, trans activating RNA (tracrRNA), and a yet-to-be-identified protein factor are involved in trimming at the 5&#x02032; end.</p></list-item><list-item id="u0050"><p id="p0110">Type 3 CRISPR/Cas system. Like the type 1 system, this category uses Cas6 for processing crRNA 3&#x02032; end trimming. The uniqueness of this technique is its targeting of RNA, which is done by a specific complex called type III Csm/Cmr complex.<xref rid="bib30" ref-type="bibr"><sup>30</sup></xref></p></list-item><list-item id="u0055"><p id="p0115">Apart from the aforementioned conventional style classification of CRISPR/Cas classification, the data review provided multiple other biotechnologies now being utilized. Some examples include photo-activating CRISPR system,<xref rid="bib31" ref-type="bibr"><sup>31</sup></xref> Intein-inducible split Cas9,<xref rid="bib32" ref-type="bibr"><sup>32</sup></xref> and modifications like hybrid crRNA-tracrRNA.<xref rid="bib33" ref-type="bibr"><sup>33</sup></xref></p></list-item><list-item id="o0035"><label>(6)</label><p id="p0120">Gene-silencing techniques. These methods may not fall truly under genome editing, but they still are capable of modifying the DNA sequence. These technologies include RNAi, CRISPR interference (CRISPRi), and morpholino oligonucleotide techniques.<xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>, <xref rid="bib36" ref-type="bibr">36</xref></p></list-item></list></p></sec><sec id="sec1.3"><title>Comparative Analysis</title><p id="p0125">The above provides a gist of the various commonly used genome-editing techniques. Though there is enormous development, innovation, and design of newer ways to edit the genome, we focus our further discussion on the comparison of common techniques, including ZFN, TALEN, and CRISPR methods. <xref rid="tbl1" ref-type="table">Tables 1</xref>, <xref rid="tbl2" ref-type="table">2</xref>, and <xref rid="tbl3" ref-type="table">3</xref> provide a comparative assessment among these methods.<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Biotechnology Differences among Prototype Genome-Editing Techniques</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Serial No.</th><th>Parameter</th><th>ZFN</th><th>TALEN</th><th>CRISPER/Cas</th><th>Reference</th></tr></thead><tbody><tr><td>1</td><td>design simplicity</td><td>moderate (ZFNs need customized protein for every DNA sequence)</td><td>slightly complex (identical repeats are multiple, which creates technical issues of engineering and delivery into cells)</td><td>simpler (available versions for crRNA can be easily designed)</td><td><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref></td></tr><tr><td>2</td><td>engineering feasibility</td><td>low</td><td>higher</td><td>highest</td><td><xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib49" ref-type="bibr">49</xref></td></tr><tr><td>3</td><td>multiplex genome editing</td><td>few models</td><td>few models</td><td>high-yield multiplexing available (no need for obtaining embryonic stem cells)</td><td><xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib50" ref-type="bibr">50</xref></td></tr><tr><td>4</td><td>large-scale library preparation</td><td>not much progress (need individual gene tailoring)</td><td>not much progress (need individual gene tailoring)</td><td>progress demonstrated (CRISPR only requires plasmid containing small oligonucleotides)</td><td><xref rid="bib51" ref-type="bibr"><sup>51</sup></xref></td></tr><tr><td>5</td><td>specificity</td><td>low</td><td>higher</td><td>highest</td><td><xref rid="bib24" ref-type="bibr"><sup>24</sup></xref></td></tr><tr><td>6</td><td>efficiency</td><td>normal<xref rid="tblfn1" ref-type="table-fn">a</xref></td><td>normal<xref rid="tblfn2" ref-type="table-fn">b</xref></td><td>high</td><td><xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib48" ref-type="bibr">48</xref>, <xref rid="bib52" ref-type="bibr">52</xref></td></tr><tr><td>7</td><td>cost</td><td>low</td><td>high</td><td>low</td><td><xref rid="bib53" ref-type="bibr"><sup>53</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>a</label><p id="ntpara0010">Some new versions are more efficient<xref rid="bib24" ref-type="bibr">24</xref>, <xref rid="bib48" ref-type="bibr">48</xref> but CRISPR science is evolving more.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tblfn2"><label>b</label><p id="ntpara0015">Cpf1 protein addition will probably improve cell delivery methods.<xref rid="bib51" ref-type="bibr">51</xref>, <xref rid="bib52" ref-type="bibr">52</xref></p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2"><label>Table 2</label><caption><p>Side Effect Profiles for Genome-Editing Methods</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Serial No.</th><th>Parameter</th><th>ZFN</th><th>TALEN</th><th>CRISPER/Cas</th><th>Reference</th></tr></thead><tbody><tr><td>1</td><td>off-target effect incidence</td><td>&#x02013;</td><td>&#x02013;</td><td>&#x02013;</td><td><xref rid="bib54" ref-type="bibr"><sup>54</sup></xref></td></tr><tr><td align="right">a</td><td>homologous recombination rate frequency</td><td>+</td><td>+</td><td>+</td><td>&#x02013;</td></tr><tr><td align="right">b</td><td>non-homologous end joining (NHEJ) mutation rates</td><td>+</td><td>+</td><td>++ (only with earlier versions)</td><td><xref rid="bib55" ref-type="bibr">55</xref>, <xref rid="bib56" ref-type="bibr">56</xref></td></tr><tr><td align="right">c</td><td>immune reaction susceptibility</td><td>less</td><td>less</td><td>more</td><td><xref rid="bib57" ref-type="bibr">57</xref>, <xref rid="bib58" ref-type="bibr">58</xref></td></tr><tr><td align="right">d</td><td>RNA-guided endonuclease (RGEN)-induced off-target mutatagenesis</td><td>&#x02212;</td><td>&#x02212;</td><td>++</td><td><xref rid="bib59" ref-type="bibr"><sup>59</sup></xref></td></tr><tr><td>2</td><td>cytotoxicity chances</td><td>++</td><td>+</td><td>+</td><td>&#x02013;</td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl3"><label>Table 3</label><caption><p>Clinical and Research Applications across Important Genome-Editing Techniques</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Serial No.</th><th>Parameter</th><th>ZFN</th><th>TALEN</th><th>CRISPER/Cas</th><th>Reference</th></tr></thead><tbody><tr><td>1</td><td>diagnostic utility</td><td>+</td><td>+</td><td>+++</td><td><xref rid="bib60" ref-type="bibr"><sup>60</sup></xref></td></tr><tr><td>2</td><td>clinical trial use</td><td>++</td><td>+</td><td>+++</td><td><xref rid="bib61" ref-type="bibr"><sup>61</sup></xref></td></tr><tr><td>3</td><td>utility as epigenetic marker</td><td>++</td><td>+++</td><td>++++</td><td><xref rid="bib62" ref-type="bibr"><sup>62</sup></xref></td></tr><tr><td>4</td><td>making gene-knockout models for research</td><td>no</td><td>no</td><td>yes (CRISPRi)</td><td><xref rid="bib63" ref-type="bibr"><sup>63</sup></xref></td></tr><tr><td>5</td><td>capacity for modification of mitochondrial DNA</td><td>no</td><td>no</td><td>probable</td><td><xref rid="bib64" ref-type="bibr"><sup>64</sup></xref></td></tr><tr><td>6</td><td>genetic editing in human babies</td><td>no</td><td>no</td><td>yes</td><td><xref rid="bib65" ref-type="bibr"><sup>65</sup></xref></td></tr><tr><td>7</td><td>RNA editing</td><td>no</td><td>no</td><td>yes</td><td><xref rid="bib66" ref-type="bibr"><sup>66</sup></xref></td></tr></tbody></table></table-wrap></p></sec><sec id="sec1.4"><title>Advancements in Genome Engineering</title><p id="p0130">The biotechnology is booming with a lot of newer modalities to edit the genome. Oligodeoxyribonucleotide (ODN) can be utilized with double-stranded transcription factor decoy (TFD) to act as a therapeutic target for multiple diseases, which can affect the transcription factor and thus bring in the requisite change in transcription and further downstream protein actions.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> Papaioannou et&#x000a0;al.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> have utilized single-stranded ODNs to precisely cut genomes for repairing very small point mutations, giving a footprint-free genome-editing modality. This concept involves a drug (doxycycline)-induced Cs9 transgene, which is carried into the cell by a specific transposon, providing us with very specific and efficient Cas9-mediated editing of the genome. This technique does not need the conventional donor template, and, thus, it is termed footprint-free genome editing.<xref rid="bib38" ref-type="bibr"><sup>38</sup></xref> The technique seems to have minimal off-target effects and is considered to be a safer version.</p><p id="p0135">Other novel modalities of genome editing are also appearing in the literature, with slight modifications of existing techniques. Mart&#x000ed;nez-G&#x000e1;lvez et&#x000a0;al.<xref rid="bib39" ref-type="bibr"><sup>39</sup></xref> used single-stranded DNA (ssDNA) and argonautes in gene editing and helped improved gene editing. Some researchers have utilized certain enzymes like integrases and in the future may obviate the need for nucleases.<xref rid="bib40" ref-type="bibr"><sup>40</sup></xref></p><p id="p0140">The most interesting part of the genome-editing technique, which may be the game changer in genome editing, is the whole genome engineering by synthesis that in fact would re-create the genome from scratch as per the given designed DNA code. This probably will become the synthetic genomics of the future.<xref rid="bib41" ref-type="bibr"><sup>41</sup></xref> Though research work in this domain stands preliminary, over time it is anticipated that this technology may overtake the concept of genome editing.</p></sec><sec id="sec1.5"><title>Bioethical Issues and Genome-Editing Techniques</title><p id="p0145">Genome-editing tools are powerful in terms of their potential to not only bring biotechnological revolution in the field of crop development and human pathology but also, in the wrong hands, lead to abuse and misuse in multiple ways, including manipulation of germline genetics. Genuine bioethical concerns have been raised by many experts.<xref rid="bib42" ref-type="bibr"><sup>42</sup></xref> While time will be the actual judge of these technologies as boon or bane, still the methods can impact the human race probably in the most nuclear ways, and our incoming human race may be victimized in ways we do not yet understand.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> Principal concerns apart from illegal germline mutation include the morality, the eugenics helping the fittest to survive, ongoing clinical debates about informed consent, religious debate, the possible rise of clones, designer babies, and possibly superhumans.<xref rid="bib44" ref-type="bibr">44</xref>, <xref rid="bib45" ref-type="bibr">45</xref>, <xref rid="bib46" ref-type="bibr">46</xref> Moreover, the current literature also rules in the possibility of genome editing as a future weapon of war.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref></p><p id="p0150">While the quest for a healthy baby and right of best possible treatment choice have been acknowledged in many societies, the approaching biotechnological revolution seems imminent and undeniable. The pressing need, therefore demands a harmonious and regulated translation of needed aspects of genome-editing-related technologies for molecular medicine and other non-clinical crop and food industries. This will need consensus in public opinion, debates among experts, involvement of biotechnologists, opinions of bioethical experts, regulatory frameworks within legislatures, and final guidelines and oversight for the finally allowed limited application.</p></sec><sec id="sec1.6"><title>Conclusions</title><p id="p0155">This review discussed multiples aspects of genome-editing technologies, including a classification; some basic explanatory concepts on mechanisms; and comparison between methods, newer advancements, and bioethical concerns. It seems that CRISPR/Cas technologies are probably superseding ZFNs and TALENS. However, the CRIPSR/Cas methods are also being improvised, and newer additions have further enhanced its functional capabilities with reduced off-target effects. Furthermore, the process of engineering better gene modification technologies is evolving and can one day replace even CRISPR/Cas, possibly shifting to synthetic genomics. Among all these revolutionary developments, bioethical concerns need serious attention.</p></sec></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Friedrich</surname><given-names>M.</given-names></name></person-group><article-title>Ueber die chemische Zusammensetzung der Eiterzellen [On the chemical composition of pus cells]</article-title><source>Medicinisch-chemische Untersuchungen</source><volume>4</volume><year>1871</year><fpage>441</fpage><lpage>460</lpage></element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>J.D.</given-names></name><name><surname>Crick</surname><given-names>F.H.C.</given-names></name></person-group><article-title>Molecular structure of nucleic acids; a structure for deoxyribose nucleic acid</article-title><source>Nature</source><volume>171</volume><year>1953</year><fpage>737</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">13054692</pub-id></element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Sanger</surname><given-names>F.</given-names></name><name><surname>Coulson</surname><given-names>A.R.</given-names></name></person-group><article-title>A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase</article-title><source>J.&#x000a0;Mol. Biol.</source><volume>94</volume><year>1975</year><fpage>441</fpage><lpage>448</lpage><pub-id pub-id-type="pmid">1100841</pub-id></element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="other" id="sref4"><person-group person-group-type="author"><name><surname>Mullis</surname><given-names>K.B.</given-names></name></person-group><ext-link ext-link-type="uri" xlink:href="https://www.karymullis.com/" id="intref0010">https://www.karymullis.com/</ext-link><year>2016</year></element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Pavletich</surname><given-names>N.P.</given-names></name><name><surname>Pabo</surname><given-names>C.O.</given-names></name></person-group><article-title>Zinc finger-DNA recognition: crystal structure of a Zif268-DNA complex at 2.1 A</article-title><source>Science</source><volume>252</volume><year>1991</year><fpage>809</fpage><lpage>817</lpage><pub-id pub-id-type="pmid">2028256</pub-id></element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Claussin</surname><given-names>C.</given-names></name><name><surname>Chang</surname><given-names>M.</given-names></name></person-group><article-title>Multiple Rad52-Mediated Homology-Directed Repair Mechanisms Are Required to Prevent Telomere Attrition-Induced Senescence in Saccharomyces cerevisiae</article-title><source>PLoS Genet.</source><volume>12</volume><year>2016</year><fpage>e1006176</fpage><pub-id pub-id-type="pmid">27428329</pub-id></element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Arai</surname><given-names>N.</given-names></name><name><surname>Kagawa</surname><given-names>W.</given-names></name></person-group><article-title>[Molecular mechanisms of homologous recombination promoted by budding yeast Rad52]</article-title><source>Seikagaku</source><volume>86</volume><year>2014</year><fpage>693</fpage><lpage>697</lpage><pub-id pub-id-type="pmid">25509340</pub-id></element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Komiyama</surname><given-names>M.</given-names></name></person-group><article-title>Chemical modifications of artificial restriction DNA cutter (ARCUT) to promote its in&#x000a0;vivo and in&#x000a0;vitro applications</article-title><source>Artif. DNA PNA XNA</source><volume>5</volume><year>2014</year><fpage>e1112457</fpage><pub-id pub-id-type="pmid">26744220</pub-id></element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Ito</surname><given-names>K.</given-names></name><name><surname>Komiyama</surname><given-names>M.</given-names></name></person-group><article-title>Site-selective scission of human genome using PNA-based artificial restriction DNA cutter</article-title><source>Methods Mol. Biol.</source><volume>1050</volume><year>2014</year><fpage>111</fpage><lpage>120</lpage><pub-id pub-id-type="pmid">24297354</pub-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Schultz</surname><given-names>B.R.</given-names></name><name><surname>Chamberlain</surname><given-names>J.S.</given-names></name></person-group><article-title>Recombinant adeno-associated virus transduction and integration</article-title><source>Mol. Ther.</source><volume>16</volume><year>2008</year><fpage>1189</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">18500252</pub-id></element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>J.</given-names></name><name><surname>Grizot</surname><given-names>S.</given-names></name><name><surname>Arnould</surname><given-names>S.</given-names></name><name><surname>Duclert</surname><given-names>A.</given-names></name><name><surname>Epinat</surname><given-names>J.C.</given-names></name><name><surname>Chames</surname><given-names>P.</given-names></name><name><surname>Prieto</surname><given-names>J.</given-names></name><name><surname>Redondo</surname><given-names>P.</given-names></name><name><surname>Blanco</surname><given-names>F.J.</given-names></name><name><surname>Bravo</surname><given-names>J.</given-names></name></person-group><article-title>A combinatorial approach to create artificial homing endonucleases cleaving chosen sequences</article-title><source>Nucleic Acids Res.</source><volume>34</volume><year>2006</year><fpage>e149</fpage><pub-id pub-id-type="pmid">17130168</pub-id></element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Yoon</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>D.</given-names></name><name><surname>Tai</surname><given-names>P.W.L.</given-names></name><name><surname>Riley</surname><given-names>J.</given-names></name><name><surname>Gao</surname><given-names>G.</given-names></name><name><surname>Rivera-P&#x000e9;rez</surname><given-names>J.A.</given-names></name></person-group><article-title>Streamlined ex&#x000a0;vivo and in&#x000a0;vivo genome editing in mouse embryos using recombinant adeno-associated viruses</article-title><source>Nat. Commun.</source><volume>9</volume><year>2018</year><fpage>412</fpage><pub-id pub-id-type="pmid">29379011</pub-id></element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Rey-Rico</surname><given-names>A.</given-names></name><name><surname>Cucchiarini</surname><given-names>M.</given-names></name></person-group><article-title>Controlled release strategies for rAAV-mediated gene delivery</article-title><source>Acta Biomater.</source><volume>29</volume><year>2016</year><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">26472612</pub-id></element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>L.</given-names></name><name><surname>Lange</surname><given-names>W.</given-names></name><name><surname>Kempmann</surname><given-names>A.</given-names></name><name><surname>Maybeck</surname><given-names>V.</given-names></name><name><surname>G&#x000fc;nther</surname><given-names>A.</given-names></name><name><surname>Gruteser</surname><given-names>N.</given-names></name><name><surname>Baumann</surname><given-names>A.</given-names></name><name><surname>Offenh&#x000e4;usser</surname><given-names>A.</given-names></name></person-group><article-title>High-efficiency transduction and specific expression of ChR2opt for optogenetic manipulation of primary cortical neurons mediated by recombinant adeno-associated viruses</article-title><source>J.&#x000a0;Biotechnol.</source><volume>233</volume><year>2016</year><fpage>171</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">27416794</pub-id></element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Zaslavskiy</surname><given-names>M.</given-names></name><name><surname>Bertonati</surname><given-names>C.</given-names></name><name><surname>Duchateau</surname><given-names>P.</given-names></name><name><surname>Duclert</surname><given-names>A.</given-names></name><name><surname>Silva</surname><given-names>G.H.</given-names></name></person-group><article-title>Efficient design of meganucleases using a machine learning approach</article-title><source>BMC Bioinformatics</source><volume>15</volume><year>2014</year><fpage>191</fpage><pub-id pub-id-type="pmid">24934562</pub-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>McMurrough</surname><given-names>T.A.</given-names></name><name><surname>Brown</surname><given-names>C.M.</given-names></name><name><surname>Zhang</surname><given-names>K.</given-names></name><name><surname>Hausner</surname><given-names>G.</given-names></name><name><surname>Junop</surname><given-names>M.S.</given-names></name><name><surname>Gloor</surname><given-names>G.B.</given-names></name><name><surname>Edgell</surname><given-names>D.R.</given-names></name></person-group><article-title>Active site residue identity regulates cleavage preference of LAGLIDADG homing endonucleases</article-title><source>Nucleic Acids Res.</source><volume>46</volume><year>2018</year><fpage>11990</fpage><lpage>12007</lpage><pub-id pub-id-type="pmid">30357419</pub-id></element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Ochiai</surname><given-names>H.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name></person-group><article-title>Construction and Evaluation of Zinc Finger Nucleases</article-title><source>Methods Mol. Biol.</source><volume>1630</volume><year>2017</year><fpage>1</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">28643245</pub-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Ji</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>P.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Qu</surname><given-names>X.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Jiang</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>X.</given-names></name><name><surname>Zhong</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>H.</given-names></name><name><surname>Pan</surname><given-names>H.</given-names></name></person-group><article-title>Zinc-Finger Nucleases Induced by HIV-1 Tat Excise HIV-1 from the Host Genome in Infected and Latently Infected Cells</article-title><source>Mol. Ther. Nucleic Acids</source><volume>12</volume><year>2018</year><fpage>67</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">30195798</pub-id></element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Hensel</surname><given-names>G.</given-names></name><name><surname>Kumlehn</surname><given-names>J.</given-names></name></person-group><article-title>Genome Engineering Using TALENs</article-title><source>Methods Mol. Biol.</source><volume>1900</volume><year>2019</year><fpage>195</fpage><lpage>215</lpage><pub-id pub-id-type="pmid">30460567</pub-id></element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Chandrasegaran</surname><given-names>S.</given-names></name><name><surname>Carroll</surname><given-names>D.</given-names></name></person-group><article-title>Origins of Programmable Nucleases for Genome Engineering</article-title><source>J.&#x000a0;Mol. Biol.</source><volume>428</volume><issue>5 Pt B</issue><year>2016</year><fpage>963</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">26506267</pub-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>S.</given-names></name><name><surname>Maier</surname><given-names>L.K.</given-names></name><name><surname>Stoll</surname><given-names>B.</given-names></name><name><surname>Brendel</surname><given-names>J.</given-names></name><name><surname>Fischer</surname><given-names>E.</given-names></name><name><surname>Pfeiffer</surname><given-names>F.</given-names></name><name><surname>Dyall-Smith</surname><given-names>M.</given-names></name><name><surname>Marchfelder</surname><given-names>A.</given-names></name></person-group><article-title>An archaeal immune system can detect multiple protospacer adjacent motifs (PAMs) to target invader DNA</article-title><source>J.&#x000a0;Biol. Chem.</source><volume>287</volume><year>2012</year><fpage>33351</fpage><lpage>33363</lpage><pub-id pub-id-type="pmid">22767603</pub-id></element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Eid</surname><given-names>A.</given-names></name><name><surname>Mahfouz</surname><given-names>M.M.</given-names></name></person-group><article-title>Genome editing: the road of CRISPR/Cas9 from bench to clinic</article-title><source>Exp. Mol. Med.</source><volume>48</volume><year>2016</year><fpage>e265</fpage><pub-id pub-id-type="pmid">27741224</pub-id></element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Wen</surname><given-names>Y.</given-names></name><name><surname>Guo</surname><given-names>X.</given-names></name></person-group><article-title>CRISPR/Cas9 for genome editing: progress, implications and challenges</article-title><source>Hum. Mol. Genet.</source><volume>23</volume><issue>R1</issue><year>2014</year><fpage>R40</fpage><lpage>R46</lpage><pub-id pub-id-type="pmid">24651067</pub-id></element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>J.H.</given-names></name><name><surname>Adikaram</surname><given-names>P.</given-names></name><name><surname>Pandey</surname><given-names>M.</given-names></name><name><surname>Genis</surname><given-names>A.</given-names></name><name><surname>Simonds</surname><given-names>W.F.</given-names></name></person-group><article-title>Optimization of genome editing through CRISPR-Cas9 engineering</article-title><source>Bioengineered</source><volume>7</volume><year>2016</year><fpage>166</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">27340770</pub-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>W.</given-names></name><name><surname>Mahmood</surname><given-names>T.</given-names></name><name><surname>Hussain</surname><given-names>J.</given-names></name><name><surname>Ali</surname><given-names>N.</given-names></name><name><surname>Shah</surname><given-names>T.</given-names></name><name><surname>Qayyum</surname><given-names>S.</given-names></name><name><surname>Khan</surname><given-names>I.</given-names></name></person-group><article-title>CRISPR/Cas system: A game changing genome editing technology, to treat human genetic diseases</article-title><source>Gene</source><volume>685</volume><year>2019</year><fpage>70</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">30393194</pub-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Zheng</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>X.</given-names></name></person-group><article-title>Delivery of CRISPR/Cas9 by novel strategies for gene therapy</article-title><source>ChemBioChem</source><volume>20</volume><year>2019</year><fpage>634</fpage><lpage>643</lpage><pub-id pub-id-type="pmid">30393919</pub-id></element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>B.</given-names></name><name><surname>Sun</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>X.</given-names></name><name><surname>Ke</surname><given-names>Y.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name></person-group><article-title>Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases</article-title><source>Hum. Genet.</source><volume>137</volume><year>2018</year><fpage>679</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">30203114</pub-id></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="other" id="sref28"><person-group person-group-type="author"><name><surname>Regalado</surname><given-names>A.</given-names></name></person-group><article-title>Exclusive: Chinese scientists are creating CRISPR babies. A daring effort is under way to create the first children whose DNA has been tailored using gene editing. MIT Technology Review</article-title><ext-link ext-link-type="uri" xlink:href="https://www.technologyreview.com/s/612458/exclusive-chinese-scientists-are-creating-crispr-babies/" id="intref0015">https://www.technologyreview.com/s/612458/exclusive-chinese-scientists-are-creating-crispr-babies/</ext-link><year>2018</year></element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Damian</surname><given-names>M.</given-names></name><name><surname>Porteus</surname><given-names>M.H.</given-names></name></person-group><article-title>A crisper look at genome editing: RNA-guided genome modification</article-title><source>Mol. Ther.</source><volume>21</volume><year>2013</year><fpage>720</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">23542565</pub-id></element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Rath</surname><given-names>D.</given-names></name><name><surname>Amlinger</surname><given-names>L.</given-names></name><name><surname>Rath</surname><given-names>A.</given-names></name><name><surname>Lundgren</surname><given-names>M.</given-names></name></person-group><article-title>The CRISPR-Cas immune system: biology, mechanisms and applications</article-title><source>Biochimie</source><volume>117</volume><year>2015</year><fpage>119</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">25868999</pub-id></element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Polstein</surname><given-names>L.R.</given-names></name><name><surname>Gersbach</surname><given-names>C.A.</given-names></name></person-group><article-title>A light-inducible CRISPR-Cas9 system for control of endogenous gene activation</article-title><source>Nat. Chem. Biol.</source><volume>11</volume><year>2015</year><fpage>198</fpage><lpage>200</lpage><pub-id pub-id-type="pmid">25664691</pub-id></element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Zetsche</surname><given-names>B.</given-names></name><name><surname>Volz</surname><given-names>S.E.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name></person-group><article-title>A split-Cas9 architecture for inducible genome editing and transcription modulation</article-title><source>Nat. Biotechnol.</source><volume>33</volume><year>2015</year><fpage>139</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">25643054</pub-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Mali</surname><given-names>P.</given-names></name><name><surname>Aach</surname><given-names>J.</given-names></name><name><surname>Stranges</surname><given-names>P.B.</given-names></name><name><surname>Esvelt</surname><given-names>K.M.</given-names></name><name><surname>Moosburner</surname><given-names>M.</given-names></name><name><surname>Kosuri</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>L.</given-names></name><name><surname>Church</surname><given-names>G.M.</given-names></name></person-group><article-title>CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering</article-title><source>Nat. Biotechnol.</source><volume>31</volume><year>2013</year><fpage>833</fpage><lpage>838</lpage><pub-id pub-id-type="pmid">23907171</pub-id></element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>S.E.</given-names></name></person-group><article-title>RNA Interference and MicroRNA-Mediated Silencing</article-title><source>Curr. Protoc. Mol. Biol.</source><volume>112</volume><year>2015</year><comment>26.1.1&#x02013;5</comment></element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>M.</given-names></name><name><surname>Yokota</surname><given-names>E.</given-names></name><name><surname>Sakuma</surname><given-names>T.</given-names></name><name><surname>Yamatsuji</surname><given-names>T.</given-names></name><name><surname>Takigawa</surname><given-names>N.</given-names></name><name><surname>Ushijima</surname><given-names>T.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name><name><surname>Fukazawa</surname><given-names>T.</given-names></name><name><surname>Naomoto</surname><given-names>Y.</given-names></name></person-group><article-title>Development of an integrated CRISPRi targeting &#x00394;Np63 for treatment of squamous cell carcinoma</article-title><source>Oncotarget</source><volume>9</volume><year>2018</year><fpage>29220</fpage><lpage>29232</lpage><pub-id pub-id-type="pmid">30018747</pub-id></element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Paul</surname><given-names>S.</given-names></name><name><surname>Caruthers</surname><given-names>M.H.</given-names></name></person-group><article-title>Synthesis of Phosphorodiamidate Morpholino Oligonucleotides and Their Chimeras Using Phosphoramidite Chemistry</article-title><source>J.&#x000a0;Am. Chem. Soc.</source><volume>138</volume><year>2016</year><fpage>15663</fpage><lpage>15672</lpage><pub-id pub-id-type="pmid">27934012</pub-id></element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Hecker</surname><given-names>M.</given-names></name><name><surname>Wagner</surname><given-names>A.H.</given-names></name></person-group><article-title>Transcription factor decoy technology: A therapeutic update</article-title><source>Biochem. Pharmacol.</source><volume>144</volume><year>2017</year><fpage>29</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">28642036</pub-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Papaioannou</surname><given-names>I.</given-names></name><name><surname>Simons</surname><given-names>J.P.</given-names></name><name><surname>Owen</surname><given-names>J.S.</given-names></name></person-group><article-title>Oligonucleotide-directed gene-editing technology: mechanisms and future prospects</article-title><source>Expert Opin. Biol. Ther.</source><volume>12</volume><year>2012</year><fpage>329</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">22321001</pub-id></element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez-G&#x000e1;lvez</surname><given-names>G.</given-names></name><name><surname>Ata</surname><given-names>H.</given-names></name><name><surname>Campbell</surname><given-names>J.M.</given-names></name><name><surname>Ekker</surname><given-names>S.C.</given-names></name></person-group><article-title>ssDNA and the Argonautes: The Quest for the Next Golden Editor</article-title><source>Hum. Gene Ther.</source><volume>27</volume><year>2016</year><fpage>419</fpage><lpage>422</lpage><pub-id pub-id-type="pmid">27230540</pub-id></element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Ledford</surname><given-names>H.</given-names></name></person-group><article-title>Beyond CRISPR: A guide to the many other ways to edit a genome</article-title><source>Nature</source><volume>536</volume><year>2016</year><fpage>136</fpage><lpage>137</lpage></element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Z.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Geng</surname><given-names>B.</given-names></name><name><surname>Jiang</surname><given-names>S.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>X.</given-names></name><name><surname>Cai</surname><given-names>Y.</given-names></name><name><surname>Dai</surname><given-names>J.</given-names></name></person-group><article-title>Whole genome engineering by synthesis</article-title><source>Sci. China Life Sci.</source><volume>61</volume><year>2018</year><fpage>1515</fpage><lpage>1527</lpage><pub-id pub-id-type="pmid">30465231</pub-id></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Krishan</surname><given-names>K.</given-names></name><name><surname>Kanchan</surname><given-names>T.</given-names></name><name><surname>Singh</surname><given-names>B.</given-names></name></person-group><article-title>Human Genome Editing and Ethical Considerations</article-title><source>Sci. Eng. Ethics</source><volume>22</volume><year>2016</year><fpage>597</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">26154417</pub-id></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Krishan</surname><given-names>K.</given-names></name><name><surname>Kanchan</surname><given-names>T.</given-names></name><name><surname>Singh</surname><given-names>B.</given-names></name><name><surname>Baryah</surname><given-names>N.</given-names></name><name><surname>Puri</surname><given-names>S.</given-names></name></person-group><article-title>Germline Editing: Editors Cautionary</article-title><source>Clin. Ter.</source><volume>169</volume><year>2018</year><fpage>e58</fpage><lpage>e59</lpage><pub-id pub-id-type="pmid">29595865</pub-id></element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Shinwari</surname><given-names>Z.K.</given-names></name><name><surname>Tanveer</surname><given-names>F.</given-names></name><name><surname>Khalil</surname><given-names>A.T.</given-names></name></person-group><article-title>Ethical Issues Regarding CRISPR Mediated Genome Editing</article-title><source>Curr. Issues Mol. Biol.</source><volume>26</volume><year>2018</year><fpage>103</fpage><lpage>110</lpage><pub-id pub-id-type="pmid">28879860</pub-id></element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>S.M.</given-names></name></person-group><article-title>Designing humans: A human rights approach</article-title><source>Bioethics</source><volume>33</volume><year>2019</year><fpage>98</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">30311673</pub-id></element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Hofmann</surname><given-names>B.</given-names></name></person-group><article-title>The gene-editing of super-ego</article-title><source>Med. Health Care Philos.</source><volume>21</volume><year>2018</year><fpage>295</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">29667122</pub-id></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Fraser</surname><given-names>C.M.</given-names></name><name><surname>Dando</surname><given-names>M.R.</given-names></name></person-group><article-title>Genomics and future biological weapons: the need for preventive action by the biomedical community</article-title><source>Nat. Genet.</source><volume>29</volume><year>2001</year><fpage>253</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">11687792</pub-id></element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>La Russa</surname><given-names>M.</given-names></name><name><surname>Qi</surname><given-names>L.S.</given-names></name></person-group><article-title>CRISPR/Cas9 in Genome Editing and Beyond</article-title><source>Annu. Rev. Biochem.</source><volume>85</volume><year>2016</year><fpage>227</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">27145843</pub-id></element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Salsman</surname><given-names>J.</given-names></name><name><surname>Dellaire</surname><given-names>G.</given-names></name></person-group><article-title>Precision genome editing in the CRISPR era</article-title><source>Biochem. Cell Biol.</source><volume>95</volume><year>2017</year><fpage>187</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">28177771</pub-id></element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Sakuma</surname><given-names>T.</given-names></name><name><surname>Nishikawa</surname><given-names>A.</given-names></name><name><surname>Kume</surname><given-names>S.</given-names></name><name><surname>Chayama</surname><given-names>K.</given-names></name><name><surname>Yamamoto</surname><given-names>T.</given-names></name></person-group><article-title>Multiplex genome engineering in human cells using all-in-one CRISPR/Cas9 vector system</article-title><source>Sci. Rep.</source><volume>4</volume><year>2014</year><fpage>5400</fpage><pub-id pub-id-type="pmid">24954249</pub-id></element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Poirier</surname><given-names>J.T.</given-names></name></person-group><article-title>CRISPR Libraries and Screening</article-title><source>Prog. Mol. Biol. Transl. Sci.</source><volume>152</volume><year>2017</year><fpage>69</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">29150005</pub-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>J.</given-names></name><name><surname>Yang</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>R.D.</given-names></name><name><surname>Chen</surname><given-names>D.</given-names></name><name><surname>Jiang</surname><given-names>Y.</given-names></name></person-group><article-title>A CRISPR-Cpf1-Assisted Non-Homologous End Joining Genome Editing System of Mycobacterium smegmatis</article-title><source>Biotechnol. J.</source><volume>13</volume><year>2018</year><fpage>e1700588</fpage><pub-id pub-id-type="pmid">30039929</pub-id></element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>X.Y.</given-names></name><name><surname>Zhu</surname><given-names>L.Y.</given-names></name><name><surname>Zhu</surname><given-names>C.S.</given-names></name><name><surname>Ma</surname><given-names>J.X.</given-names></name><name><surname>Hou</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>X.M.</given-names></name><name><surname>Xie</surname><given-names>S.S.</given-names></name><name><surname>Min</surname><given-names>L.</given-names></name><name><surname>Tan</surname><given-names>D.A.</given-names></name><name><surname>Zhang</surname><given-names>D.Y.</given-names></name><name><surname>Zhu</surname><given-names>L.</given-names></name></person-group><article-title>Highly Effective and Low-Cost MicroRNA Detection with CRISPR-Cas9</article-title><source>ACS Synth. Biol.</source><volume>7</volume><year>2018</year><fpage>807</fpage><lpage>813</lpage><pub-id pub-id-type="pmid">29486117</pub-id></element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Koo</surname><given-names>T.</given-names></name><name><surname>Lee</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>J.S.</given-names></name></person-group><article-title>Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9</article-title><source>Mol. Cells</source><volume>38</volume><year>2015</year><fpage>475</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">25985872</pub-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Symington</surname><given-names>L.S.</given-names></name><name><surname>Gautier</surname><given-names>J.</given-names></name></person-group><article-title>Double-strand break end resection and repair pathway choice</article-title><source>Annu. Rev. Genet.</source><volume>45</volume><year>2011</year><fpage>247</fpage><lpage>271</lpage><pub-id pub-id-type="pmid">21910633</pub-id></element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>H.</given-names></name><name><surname>Xue</surname><given-names>W.</given-names></name><name><surname>Chen</surname><given-names>S.</given-names></name><name><surname>Bogorad</surname><given-names>R.L.</given-names></name><name><surname>Benedetti</surname><given-names>E.</given-names></name><name><surname>Grompe</surname><given-names>M.</given-names></name><name><surname>Koteliansky</surname><given-names>V.</given-names></name><name><surname>Sharp</surname><given-names>P.A.</given-names></name><name><surname>Jacks</surname><given-names>T.</given-names></name><name><surname>Anderson</surname><given-names>D.G.</given-names></name></person-group><article-title>Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype</article-title><source>Nat. Biotechnol.</source><volume>32</volume><year>2014</year><fpage>551</fpage><lpage>553</lpage><pub-id pub-id-type="pmid">24681508</pub-id></element-citation></ref><ref id="bib57"><label>57</label><element-citation publication-type="journal" id="sref57"><person-group person-group-type="author"><name><surname>Jordan</surname><given-names>B.</given-names></name></person-group><article-title>Les d&#x000e9;buts de CRISPR en th&#x000e9;rapie g&#x000e9;nique - Chroniques g&#x000e9;nomiques [First use of CRISPR for gene therapy]</article-title><source>Med. Sci. (Paris)</source><volume>32</volume><year>2016</year><fpage>1035</fpage><lpage>1037</lpage><pub-id pub-id-type="pmid">28008849</pub-id></element-citation></ref><ref id="bib58"><label>58</label><element-citation publication-type="journal" id="sref58"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>W.L.</given-names></name></person-group><article-title>Immunity to CRISPR Cas9 and Cas12a therapeutics</article-title><source>Wiley Interdiscip. Rev. Syst. Biol. Med.</source><volume>10</volume><year>2018</year></element-citation></ref><ref id="bib59"><label>59</label><element-citation publication-type="journal" id="sref59"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>S.W.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>Y.</given-names></name><name><surname>Kweon</surname><given-names>J.</given-names></name><name><surname>Kim</surname><given-names>H.S.</given-names></name><name><surname>Bae</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>J.S.</given-names></name></person-group><article-title>Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases</article-title><source>Genome Res.</source><volume>24</volume><year>2014</year><fpage>132</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">24253446</pub-id></element-citation></ref><ref id="bib60"><label>60</label><element-citation publication-type="journal" id="sref60"><person-group person-group-type="author"><name><surname>Shang</surname><given-names>W.</given-names></name><name><surname>Wang</surname><given-names>F.</given-names></name><name><surname>Fan</surname><given-names>G.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name></person-group><article-title>Key elements for designing and performing a CRISPR/Cas9-based genetic screen</article-title><source>J.&#x000a0;Genet. Genomics</source><volume>44</volume><year>2017</year><fpage>439</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">28967615</pub-id></element-citation></ref><ref id="bib61"><label>61</label><element-citation publication-type="journal" id="sref61"><person-group person-group-type="author"><name><surname>Wassef</surname><given-names>M.</given-names></name><name><surname>Luscan</surname><given-names>A.</given-names></name><name><surname>Battistella</surname><given-names>A.</given-names></name><name><surname>Le Corre</surname><given-names>S.</given-names></name><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Wallace</surname><given-names>M.R.</given-names></name><name><surname>Vidaud</surname><given-names>M.</given-names></name><name><surname>Margueron</surname><given-names>R.</given-names></name></person-group><article-title>Versatile and precise gene-targeting strategies for functional studies in mammalian cell lines</article-title><source>Methods</source><volume>121-122</volume><year>2017</year><fpage>45</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">28499832</pub-id></element-citation></ref><ref id="bib62"><label>62</label><element-citation publication-type="journal" id="sref62"><person-group person-group-type="author"><name><surname>Vojta</surname><given-names>A.</given-names></name><name><surname>Dobrini&#x00107;</surname><given-names>P.</given-names></name><name><surname>Tadi&#x00107;</surname><given-names>V.</given-names></name><name><surname>Bo&#x0010d;kor</surname><given-names>L.</given-names></name><name><surname>Kora&#x00107;</surname><given-names>P.</given-names></name><name><surname>Julg</surname><given-names>B.</given-names></name><name><surname>Klasi&#x00107;</surname><given-names>M.</given-names></name><name><surname>Zoldo&#x00161;</surname><given-names>V.</given-names></name></person-group><article-title>Repurposing the CRISPR-Cas9 system for targeted DNA methylation</article-title><source>Nucleic Acids Res.</source><volume>44</volume><year>2016</year><fpage>5615</fpage><lpage>5628</lpage><pub-id pub-id-type="pmid">26969735</pub-id></element-citation></ref><ref id="bib63"><label>63</label><element-citation publication-type="journal" id="sref63"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>B.</given-names></name><name><surname>Yang</surname><given-names>Q.</given-names></name><name><surname>Chen</surname><given-names>J.</given-names></name><name><surname>Wu</surname><given-names>L.</given-names></name><name><surname>Yao</surname><given-names>T.</given-names></name><name><surname>Wu</surname><given-names>Y.</given-names></name><name><surname>Xu</surname><given-names>H.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Xia</surname><given-names>Q.</given-names></name><name><surname>Zhou</surname><given-names>D.</given-names></name></person-group><article-title>CRISPRi-Manipulation of Genetic Code Expansion via RF1 for Reassignment of Amber Codon in Bacteria</article-title><source>Sci. Rep.</source><volume>6</volume><year>2016</year><fpage>20000</fpage><pub-id pub-id-type="pmid">26818534</pub-id></element-citation></ref><ref id="bib64"><label>64</label><element-citation publication-type="journal" id="sref64"><person-group person-group-type="author"><name><surname>Fogleman</surname><given-names>S.</given-names></name><name><surname>Santana</surname><given-names>C.</given-names></name><name><surname>Bishop</surname><given-names>C.</given-names></name><name><surname>Miller</surname><given-names>A.</given-names></name><name><surname>Capco</surname><given-names>D.G.</given-names></name></person-group><article-title>CRISPR/Cas9 and mitochondrial gene replacement therapy: promising techniques and ethical considerations</article-title><source>Am. J. Stem Cells</source><volume>5</volume><year>2016</year><fpage>39</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">27725916</pub-id></element-citation></ref><ref id="bib65"><label>65</label><element-citation publication-type="journal" id="sref65"><person-group person-group-type="author"><name><surname>Callaway</surname><given-names>E.</given-names></name></person-group><article-title>Gene-editing research in human embryos gains momentum</article-title><source>Nature</source><volume>532</volume><year>2016</year><fpage>289</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">27111607</pub-id></element-citation></ref><ref id="bib66"><label>66</label><element-citation publication-type="other" id="sref66"><person-group person-group-type="author"><name><surname>Zimmer</surname><given-names>C.</given-names></name></person-group><article-title>Scientists Find Form of Crispr Gene Editing With New Capabilities. The New York Times, June 3, 2016</article-title><ext-link ext-link-type="uri" xlink:href="https://www.nytimes.com/2016/06/04/science/rna-c2c2-gene-editing-dna-crispr.html" id="intref0020">https://www.nytimes.com/2016/06/04/science/rna-c2c2-gene-editing-dna-crispr.html</ext-link><year>2016</year></element-citation></ref></ref-list></back></article>